Medtronic Wins FDA Approval for Altaviva Urinary Incontinence Device
Medtronic announced FDA approval of the Altaviva device, designed to treat urge urinary incontinence (UUI). The device is a minimally invasive, implantable tibial neuromodulation (ITNM) therapy inserted near the ankle. Altaviva is intended for patients who do not feel comfortable with invasive therapies, given the potential side effects.
The device is designed to have a 15-year battery lifespan, requiring no daily adjustments. It is MRI compatible and requires only 30 minutes of recharging. Medtronic, which has been investing heavily in connected care, is positioning Altaviva as part of its broader strategy to expand patient access and simplify treatment.
Posted by MedCloudInsider Editors on 09/26/2025